Dergiler / Gülhane Tıp Dergisi / 2020 / Cilt: 62 - Sayı: 1

Does the efficacy of different doses of Botulinum neurotoxin in chronic migraine change in terms of age and sex?

Sayfa
51–56
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, the efficacy of 2.5 U of BoNTA treatment was seen to be superior in the elderly population compared to the younger population.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: The aim of this study was to investigate the effectiveness of Botulinum toxin A (BoNTA) treatment at different doses according to age and sex.
📊
Temel Bulgular & Veri:Methods: In this study, 53 patients diagnosed as chronic migraine (CM) were evaluated.
💡
Sonuç & Katkı:However, the efficacy of 2.5 U of BoNTA treatment was seen to be superior in the elderly population compared to the younger population.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aim: The aim of this study was to investigate the effectiveness of Botulinum toxin A (BoNTA) treatment at different doses according to age and sex. Methods: In this study, 53 patients diagnosed as chronic migraine (CM) were evaluated. The patients were divided into four groups. Group 1a (n=13) were elderly patients who received 5 U BoNTA. Group 1b (n=13) were elderly patients who received 2.5 U BoNTA. Group 2a (n=14) were young patients who received 5 U BoNTA. Group 2b (n=13) were young patients who received 2.5 U BoNTA. In all patients, the number of headache days and the severity of pain were compared before and after the treatment. Results: There was a statistically significant difference between the number of headache days and the severity of pain in group 1a, group 1b, and group 2a at 3-month post-treatment (p<0.05). In the comparison between the groups, there was a statistically significant decrease in pain intensity in group 1b compared to group 2b in which 2.5 U BoNTA was applied (p<0.05). Conclusion: In the treatment of CM, 5 U BoNTA applications were found to be an effective treatment method in both young and old population. However, the efficacy of 2.5 U of BoNTA treatment was seen to be superior in the elderly population compared to the younger population.

🔖

Bu Makaleye Atıf Yap

ÖZÖN, A. Ö. (2020). Does the efficacy of different doses of Botulinum neurotoxin in chronic migraine change in terms of age and sex?. Gülhane Tıp Dergisi, Cilt: 62 - Sayı: 1, 51–56. https://ajindex.com/articles/158900

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain. 2019:25;20:41
  2. Arbab MA, Wiklund L, Svendgaard NA. Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat. Neuroscience. 1986;19:695-708
  3. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988:23:193-196
  4. Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology. 2001;57:132-134
  5. Deen M, Martinelli D, Pijpers J, et al. Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia. 2019;39:1058-1066
  6. Karadaş Ö, Özön AÖ, Özçelik F, Özge A. Greater occipital nerve block in the treatment of triptan-overuse headache: A randomized comparative study. Acta Neurol Scand. 2017;135:426-433
  7. Inan LE, Inan N, Karadaş Ö, Gül HL, Erdemoğlu AK, Türkel Y, Akyol A. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand. 2015;132:270-277
  8. Gul HL, Ozon AO, Karadas O, Koc G, Inan LE. The efficacy of greater occipital nerve blockade in chronic migraine: A placebo-controlled study. Acta Neurol Scand. 2017;136:138-144
  9. Do TP, Hvedstrup J, Schytz HW. Botulinum toxin: A review of the mode of action in migraine. Acta Neurol Scand. 2018;137:442-451
  10. Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain. 2017:18:78
  11. Winner PK, Blumenfeld AM, Eross EJ, Orejudos AC, Mirjah DL, Adams AM, Brin MF. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patientswith Chronic Migraine: Results of the COMPEL Study. Drug Saf. 2019;42:1013-1024
  12. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000;40:445-450.